How AI and a Menopause Drug Could Revolutionize Breast Cancer Prevention
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
In this short but powerful episode, Georgie breaks down two groundbreaking developments in breast cancer prevention that could reshape how we think about screening, menopause care, and early intervention:
1️⃣ An FDA-authorized AI tool—Clairity Breast—that predicts a woman’s five-year breast cancer risk from a standard mammogram, even when it appears normal.
2️⃣ A menopause drug, Duavee, that may help prevent invasive breast cancer in women with a history of high-risk lesions like DCIS.
These tools aren’t just high-tech—they’re practical, accessible, and represent a smarter, more equitable approach to women’s health.
Whether you're a clinician, policymaker, or woman navigating your own care, this episode breaks down what you need to know.
🔍 What You'll Learn in This Episode✅ FDA-Approved AI for Breast Cancer Risk Prediction
- What Clairity Breast is and how it works
- Why it matters for women under 50
- How it fits into current mammogram workflows
- Timeline for rollout and insurance coverage considerations
✅ Menopause Drug Duavee and Breast Cancer Prevention
- New clinical trial results shared at the ASCO 2025 meeting
- Why this treatment could benefit women with DCIS or other precancerous lesions
- What clinicians and high-risk patients should be asking now
- Duavee’s current FDA status and reimbursement landscape
✅ The Bigger Picture: Why This Is a Turning Point in Women's Health
- What these two tools signal about the future of precision and prevention
- How they're designed to work in real-world care—not just research labs
- Why this episode matters for people advocating for smarter, faster, fairer care
🎯 Who This Episode Is For
- Women navigating breast cancer risk or menopause decisions
- Clinicians, radiologists, and OB-GYNs focused on patient-centered care
- Healthcare innovators, startup leaders, and payers interested in smarter early intervention
- Policy leaders and health equity advocates
📌 Resources & References
- Read about Clairity Breast – FDA De Novo authorization details
- Learn about Duavee – Clinical trial results presented at ASCO 2025
- Check out the blog post of this episode: Breast Cancer Prevention Just Leveled Up: What Two Breakthroughs Mean for the Future of Women’s Health
📣 Help Spread the Word
If this episode helped you understand the future of breast cancer prevention, share it with a friend or clinician who needs to hear it.
🎧 Loved the episode? Here's how you can take action:1. Help others discover Fempower Health:
Leave a quick review on Apple or Spotify. It’s the easiest way to support our mission and amplify women’s health voices.
2. Stay connected:
Follow us on LinkedIn,